Home Tags Cytomx

Tag: Cytomx

FDA Accepts Investigational New Drug Application for CTLA-4 Probody Therapeutic

Bristol-Myers Squibb has received acceptance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for a CTLA-4-directed Probody™...

CytomX and AbbVie Jointly Develop and Commercialize Probody-drug Conjugates Directed...

Antibody-drug conjugates or ADCs combine the cytotoxic potential of chemotherapeutic drugs with the specificity of monoclonal antibodies.  One of the critical parameters effecting the efficacy,...

CytomX Therapeutics and Bristol-Myers Squibb Continue Collaboration

CytomX Therapeutics, an oncology-focused biopharmaceutical company based in South San Francisco developing investigational Probody™ therapeutics for the treatment of cancer, earlier today announced that...

Texas MD Anderson Cancer Center and CytomX Therapeutics Agree to Jointly...

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, and The University of Texas MD Anderson Cancer Center have agreed...

Leading Experts in Cancer Immunotherapy and Antibody-drug Conjugates Join CytomX Scientific...

CytomX Therapeutics, Inc (343 Oyster Point Boulevard #100, South San Francisco, CA 94080), a biotechnology company developing Probody™ therapeutics for the treatment of cancer,...